Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor

A common feature of many metabolic pathways is their control by retinoid X receptor (RXR) heterodimers. Dysregulation of such metabolic pathways can lead to the development of atherosclerosis, a disease influenced by both systemic and local factors. Here we analyzed the effects of activation of RXR and some of its heterodimers in apolipoprotein E −/− mice, a well established animal model of atherosclerosis. An RXR agonist drastically reduced the development of atherosclerosis. In addition, a ligand for the peroxisome proliferator-activated receptor (PPAR)γ and a dual agonist of both PPARα and PPARγ had moderate inhibitory effects. Both RXR and liver X receptor (LXR) agonists induced ATP-binding cassette protein 1 (ABC-1) expression and stimulated ABC-1-mediated cholesterol efflux from macrophages from wild-type, but not from LXRα and β double −/−, mice. Hence, activation of ABC-1-mediated cholesterol efflux by the RXR/LXR heterodimer might contribute to the beneficial effects of rexinoids on atherosclerosis and warrant further evaluation of RXR/LXR agonists in prevention and treatment of atherosclerosis.

[1]  Christopher K. Glass,et al.  The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation , 1998, Nature.

[2]  V. Pasceri,et al.  Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. , 2000, Circulation.

[3]  C. Glass,et al.  Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein , 1998 .

[4]  D. Rader,et al.  Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[5]  Andrew C. Li,et al.  Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice , 2000 .

[6]  M. Cantorna,et al.  In vitamin A deficiency multiple mechanisms establish a regulatory T helper cell imbalance with excess Th1 and insufficient Th2 function. , 1994, Journal of immunology.

[7]  E. Olson,et al.  Retinoid receptor expression and all-trans retinoic acid-mediated growth inhibition in vascular smooth muscle cells. , 1996, Circulation.

[8]  R. Evans,et al.  Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.

[9]  R. Eckel,et al.  Metabolic effects of rexinoids: tissue-specific regulation of lipoprotein lipase activity. , 2001, Molecular pharmacology.

[10]  P. Libby,et al.  Macrophages in Human Atheroma Contain PPARγ: Differentiation-Dependent Peroxisomal Proliferator-Activated Receptor γ (PPARγ) Expression and Reduction of MMP-9 Activity through PPARγ Activation in Mononuclear Phagocytes in Vitro , 1998 .

[11]  A. Tall,et al.  Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.

[12]  L. Hamann,et al.  Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists , 1997, Nature.

[13]  N. Maeda,et al.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. , 1992, Science.

[14]  R. Ross,et al.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[15]  D. Mangelsdorf,et al.  Human White/Murine ABC8 mRNA Levels Are Highly Induced in Lipid-loaded Macrophages , 2000, The Journal of Biological Chemistry.

[16]  P. Libby,et al.  Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. , 1998, Circulation research.

[17]  R. Hammer,et al.  Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα , 1998, Cell.

[18]  J. Qiao,et al.  Influence of the apoA-II gene locus on HDL levels and fatty streak development in mice. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[19]  J. Auwerx,et al.  Alterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice* , 1997, The Journal of Biological Chemistry.

[20]  Philippe Kastner,et al.  Nonsteroid nuclear receptors: What Are genetic studies telling us about their role in real life? , 1995, Cell.

[21]  E. Rubin,et al.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells , 1992, Cell.

[22]  P. Colville-Nash,et al.  Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1. , 1998, Journal of immunology.

[23]  A. Rigotti,et al.  A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Evans,et al.  PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.

[25]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[26]  D. Mangelsdorf,et al.  Nuclear receptor regulation of cholesterol and bile acid metabolism. , 1999, Current opinion in biotechnology.

[27]  M. Wilkins,et al.  Inhibition of nitric oxide synthesis in vascular smooth muscle by retinoids , 1994, British journal of pharmacology.

[28]  B. Aggarwal,et al.  Inhibition by all‐trans‐retinoic acid of tumor necrosis factor and nitric oxide production by peritoneal macrophages , 1994, Journal of leukocyte biology.

[29]  W. Miller,et al.  Induction of apoptosis without differentiation by retinoic acid in PLB-985 cells requires the activation of both RAR and RXR. , 1997, Blood.

[30]  N. Maeda,et al.  Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[31]  E. Edelman,et al.  Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels , 1997, Nature.

[32]  R. Sampliner,et al.  The effects of 13‐cis‐retinoic acid and beta‐carotene on cellular immunity in humans , 1991, Cancer.

[33]  D. Mangelsdorf,et al.  Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. , 2000, Science.

[34]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[35]  S. Tanaka,et al.  Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. , 1998, The Journal of clinical endocrinology and metabolism.

[36]  B. Seed,et al.  PPAR-γ agonists inhibit production of monocyte inflammatory cytokines , 1998, Nature.

[37]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[38]  Y. Takahashi,et al.  Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.